Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class, Therapy, End User - Global Forecast 2025-2030- Product Image

Sale

Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class, Therapy, End User - Global Forecast 2025-2030

Report
181 Pages
October 2024
Region: Global
360iResearch™
ID: 4989822

UP TO €692EUR$697USD£574GBP OFF until Dec 31^st 2024

The Benign Prostatic Hyperplasia Treatment Market grew from USD 8.58 billion in 2023 to USD 9.17 billion in 2024. It is expected to continue growing at a CAGR of 6.97%, reaching USD 13.76 billion by 2030.

The scope and definition of the Benign Prostatic Hyperplasia (BPH) Treatment market encompass a range of pharmaceuticals, minimally invasive procedures, and surgical interventions aimed at alleviating symptoms of BPH, a non-cancerous enlargement of the prostate gland that primarily affects aging males. This condition often causes urinary problems, necessitating treatments that enhance quality of life. The necessity of BPH treatment is underscored by the growing elderly population globally, heightening demand for effective therapeutic solutions. Key applications of BPH treatments include alpha-blockers, 5-alpha reductase inhibitors, and transurethral resection of the prostate, among others, catering to various severity levels of the condition. The primary end-users are hospitals, clinics, and ambulatory surgical centers, which utilize these treatments to manage and alleviate symptoms in patients.

Market insights reveal several key factors influencing growth, such as increasing healthcare expenditure, technological advancements in surgical methods, and heightened awareness of prostate health. Additionally, the increasing incidence of BPH, driven by lifestyle changes and dietary habits, presents significant market opportunities. New minimally invasive treatments and drugs, as well as innovations in combination therapies, represent potential growth avenues. The latest potential opportunities lie in developing patient-centric therapies with fewer side effects and shorter recovery times, expanding market penetration in emerging economies, and leveraging telemedicine advancements for improved disease management.

However, the BPH treatment market faces challenges such as high costs associated with advanced surgical techniques and the risk of side effects from medication, which may deter patient compliance. Regulatory approvals and stringent healthcare policies can also slow down the introduction of new treatments, affecting market growth. Areas ripe for innovation include the development of non-invasive diagnostic tools, novel biomarkers for early detection, and precision medicine approaches tailored to individual patient needs. The market is inherently dynamic, characterized by a continuous evolution of treatment methods, competitive pricing pressures, and changing patient preferences. Businesses should focus on strategic partnerships, investing in R&D, and adopting holistic patient care models to excel in this burgeoning market landscape.

Understanding Market Dynamics in the Benign Prostatic Hyperplasia Treatment Market

The Benign Prostatic Hyperplasia Treatment Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Growth in cases of benign prostatic hyperplasia
- Favorable reimbursement for surgeries and drug and treatemnt approvals
- Government investments in improving healthcare infrastructure
Market Restraints
- Side-effects related to BPH treatment
Market Opportunities
- Emergence of minimally invasive treatments for benign prostatic hyperplasia
- Ongoing research & development regarding benign prostatic hyperplasia
Market Challenges
- Lack of efficacy of treatments

Exploring Porter’s Five Forces for the Benign Prostatic Hyperplasia Treatment Market

Porter’s Five Forces framework further strengthens the insights of the Benign Prostatic Hyperplasia Treatment Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Benign Prostatic Hyperplasia Treatment Market

External macro-environmental factors deeply influence the performance of the Benign Prostatic Hyperplasia Treatment Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Benign Prostatic Hyperplasia Treatment Market

The Benign Prostatic Hyperplasia Treatment Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Benign Prostatic Hyperplasia Treatment Market

The Benign Prostatic Hyperplasia Treatment Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Benign Prostatic Hyperplasia Treatment Market

The Benign Prostatic Hyperplasia Treatment Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Benign Prostatic Hyperplasia Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Asahi Kasei Corporation, Astellas Pharma Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Eli Lilly and Company, Endo International PLC, GlaxoSmithKline plc, Merck KGaA, Mylan N.V., Pfizer, Inc., Sanofi S.A., Teleflex Incorporated, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Benign Prostatic Hyperplasia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Therapeutic Class
- 5-Alpha Reductase Inhibitor
- Alpha-Blocker
- Phosphodiesterase-5 Inhibitor
Therapy
- Combination Drug Therapy
- Mono Drug Therapy
End User
- Ambulatory Surgical Centers
- Hospitals
- Specialty Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growth in cases of benign prostatic hyperplasia
5.1.1.2. Favorable reimbursement for surgeries and drug and treatemnt approvals
5.1.1.3. Government investments in improving healthcare infrastructure
5.1.2. Restraints
5.1.2.1. Side-effects related to BPH treatment
5.1.3. Opportunities
5.1.3.1. Emergence of minimally invasive treatments for benign prostatic hyperplasia
5.1.3.2. Ongoing research & development regarding benign prostatic hyperplasia
5.1.4. Challenges
5.1.4.1. Lack of efficacy of treatments
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Benign Prostatic Hyperplasia Treatment Market, by Therapeutic Class

6.1. Introduction
6.2. 5-Alpha Reductase Inhibitor
6.3. Alpha-Blocker
6.4. Phosphodiesterase-5 Inhibitor

7. Benign Prostatic Hyperplasia Treatment Market, by Therapy

7.1. Introduction
7.2. Combination Drug Therapy
7.3. Mono Drug Therapy

8. Benign Prostatic Hyperplasia Treatment Market, by End User

8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Hospitals
8.4. Specialty Clinics

9. Americas Benign Prostatic Hyperplasia Treatment Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Benign Prostatic Hyperplasia Treatment Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA-BLOCKER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COMBINATION DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MONO DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 28. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 29. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 30. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 32. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 33. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 46. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 47. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 49. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 50. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 55. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 56. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 73. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 74. THAILAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 83. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 84. DENMARK BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 86. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 87. EGYPT BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 89. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 90. FINLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 92. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 93. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 95. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 96. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 101. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 102. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 110. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 111. NORWAY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 113. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 114. POLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 116. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 117. QATAR BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 128. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 129. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 137. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 138. TURKEY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 146. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Benign Prostatic Hyperplasia Treatment market, which are profiled in this report, include:

Abbott Laboratories
AbbVie Inc.
Asahi Kasei Corporation
Astellas Pharma Inc.
Boehringer Ingelheim GmbH
Boston Scientific Corporation
Eli Lilly and Company
Endo International PLC
GlaxoSmithKline plc
Merck KGaA
Mylan N.V.
Pfizer, Inc.
Sanofi S.A.
Teleflex Incorporated
Teva Pharmaceutical Industries Ltd.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	181
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 9.17 Billion
Forecasted Market Value ( USD ) by 2030	$ 13.76 Billion
Compound Annual Growth Rate	6.9%
Regions Covered	Global
No. of Companies Mentioned	15

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3518EUR$3,545USD£2,919GBP €3909EUR$3,939USD£3,243GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6224EUR$6,272USD£5,164GBP €6915EUR$6,969USD£5,738GBP

Understanding Market Dynamics in the Benign Prostatic Hyperplasia Treatment Market

Exploring Porter’s Five Forces for the Benign Prostatic Hyperplasia Treatment Market

Applying PESTLE Analysis to the Benign Prostatic Hyperplasia Treatment Market

Analyzing Market Share in the Benign Prostatic Hyperplasia Treatment Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Benign Prostatic Hyperplasia Treatment Market

Strategic Recommendations for Success in the Benign Prostatic Hyperplasia Treatment Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report

Benign prostatic hyperplasia (BPH) - Market Insight, Epidemiology and Market Forecast - 2034

Benign Prostatic Hyperplasia (BPH) Treatment Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)

Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032

Benign Prostatic Hyperplasia Treatment Devices Market

About the Benign Prostatic Hyperplasia Drug Market